MOB Share Price Performance
SEK 9.32
-0.13 (-1.38%)
28.3% undervalued intrinsic discount
SEK 13.00
Fair Value
Price SEK 9.32
AnalystConsensusTarget SEK 13.00
Fair ValueSEK 13.00
Share Pricen/a
Moberg Pharma AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
MOB Community Narratives
AN
Fair Value SEK 13 28.3% undervalued intrinsic discount
Norway Expansion And EU Approvals Will Strengthen Future Position
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Norway Expansion And EU Approvals Will Strengthen Future Position
Key Takeaways Expansion in Norway and obtaining EU approvals bolster revenue potential and support Moberg Pharma's European growth strategy. Retaining full rights to MOB-015 improves margins and control over commercialization, with supply chain enhancements ensuring stable product availability.Read more
56
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
SEK 13
28.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
88% p.a.
Profit Margin
3.69%
Future PE
231.12x
Price in 2029
SEK 14.78
Trending Discussion
Recently Updated Narratives
AN
MOB: Europe Licensing Agreement Will Support Future Share Price Upside
Fair Value: SEK 13 28.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Moberg Pharma AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 17, 2026
- -5.48
- 52.35%
- -2,062.80%
- 0%
About MOB
- Founded
- 2006
- Employees
- 6
- CEO
- WebsiteView website
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
